{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:55:27Z","timestamp":1784566527145,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12325-017-0589-5","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T23:52:32Z","timestamp":1502236352000},"page":"2043-2057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey"],"prefix":"10.1007","volume":"34","author":[{"name":"On behalf of the BALKAN-AF Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S.","family":"Potpara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Trendafilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe-Andrei","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artan","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zumreta","family":"Kusljugic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sime","family":"Manola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljilja","family":"Music","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gjini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belma","family":"Pojskic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea Ioakim","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina Arsenescu","family":"Georgescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S.","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delyana","family":"Kamenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uliks","family":"Ekmeciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mrsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Nenezic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Brusich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdjan","family":"Milanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zeljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719\u201347.","journal-title":"Eur Heart J"},{"key":"589_CR2","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893\u20132962.","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1160\/TH14-03-0228","volume":"111","author":"S Husted","year":"2014","unstructured":"Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost. 2014;111:781\u20132.","journal-title":"Thromb Haemost"},{"key":"589_CR4","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J. 2014;35:3365\u201376.","journal-title":"Eur Heart J"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"e004037","DOI":"10.1161\/JAHA.116.004037","volume":"5","author":"JC Hsu","year":"2016","unstructured":"Hsu JC, Akao M, Abe M, et al. International collaborative partnership for the study of atrial fibrillation (INTERAF): rationale, design, and initial descriptives. J Am Heart Assoc. 2016;5:e004037.","journal-title":"J Am Heart Assoc"},{"key":"589_CR6","first-page":"1943","volume":"36","author":"TS Potpara","year":"2015","unstructured":"Potpara TS, Balkan AFI, Lip GY. Patterns in atrial fibrillation management and \u2018real-world\u2019 adherence to guidelines in the Balkan Region: an overview of the Balkan-atrial fibrillation survey. Eur Heart J. 2015;36:1943\u20134.","journal-title":"Eur Heart J"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/eut263","volume":"16","author":"P Kirchhof","year":"2014","unstructured":"Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the prevention of thromboemolic events\u2014European registry in atrial fibrillation (PREFER in AF). Europace. 2014;16:6\u201314.","journal-title":"Europace"},{"issue":"1","key":"589_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/joim.12360","volume":"278","author":"AM Shields","year":"2015","unstructured":"Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med. 2015;278(1):1\u20138.","journal-title":"J Intern Med"},{"key":"589_CR9","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","volume":"125","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298\u2013307.","journal-title":"Circulation"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1160\/TH11-11-0784","volume":"107","author":"A Banerjee","year":"2012","unstructured":"Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584\u20139.","journal-title":"Thromb Haemost"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1160\/TH14-02-0118","volume":"111","author":"F Skjoth","year":"2014","unstructured":"Skjoth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost. 2014;111:981\u20138.","journal-title":"Thromb Haemost"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"20432","DOI":"10.1038\/srep20432","volume":"6","author":"TS Potpara","year":"2016","unstructured":"Potpara TS, Dan GA, Trendafilova E, et al. Stroke prevention in atrial fibrillation and \u2018real world\u2019 adherence to guidelines in the Balkan Region: the Balkan-AF survey. Sci Rep. 2016;6:20432.","journal-title":"Sci Rep"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/MLR.0000000000000549","volume":"54","author":"WH Lo-Ciganic","year":"2016","unstructured":"Lo-Ciganic WH, Gellad WF, Huskamp HA, et al. Who were the early adopters of dabigatran?: an application of group-based trajectory models. Med Care. 2016;54:725\u201332.","journal-title":"Med Care"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","volume":"115","author":"EM Hylek","year":"2007","unstructured":"Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689\u201396.","journal-title":"Circulation"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","volume":"35","author":"L Azoulay","year":"2014","unstructured":"Azoulay L, Dell\u2019Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014;35:1881\u20137.","journal-title":"Eur Heart J"},{"key":"589_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1160\/TH13-06-0443","volume":"110","author":"R Caterina De","year":"2013","unstructured":"De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (section iii). Position paper of the ESC working group on thrombosis\u2013task force on anticoagulants in heart disease. Thromb Haemost. 2013;110:1087\u2013107.","journal-title":"Thromb Haemost"},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1160\/TH13-12-1032","volume":"111","author":"EM Hylek","year":"2014","unstructured":"Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin k antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost. 2014;111:783\u20138.","journal-title":"Thromb Haemost"},{"key":"589_CR18","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","volume":"35","author":"R Caterina De","year":"2014","unstructured":"De Caterina R, Camm AJ. What is \u2018valvular\u2019 atrial fibrillation? A reappraisal. Eur Heart J. 2014;35:3328\u201335.","journal-title":"Eur Heart J"},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology working group on thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155\u201379.","journal-title":"Eur Heart J"},{"key":"589_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","volume":"388","author":"B Freedman","year":"2016","unstructured":"Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016;388:806\u201317.","journal-title":"Lancet"},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1160\/TH15-10-0825","volume":"114","author":"TS Potpara","year":"2015","unstructured":"Potpara TS. Dabigatran in \u2018real-world\u2019 clinical practice for stroke prevention in patients with nonvalvular atrial fibrillation. Thromb Haemost. 2015;114:1093\u20138.","journal-title":"Thromb Haemost"},{"key":"589_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1160\/TH16-05-0403","volume":"116","author":"GY Lip","year":"2016","unstructured":"Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975\u201386.","journal-title":"Thromb Haemost"},{"issue":"6","key":"589_CR23","doi-asserted-by":"publisher","first-page":"003725","DOI":"10.1161\/JAHA.116.003725","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):003725.","journal-title":"J Am Heart Assoc"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"i3189","DOI":"10.1136\/bmj.i3189","volume":"353","author":"TB Larsen","year":"2016","unstructured":"Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.","journal-title":"BMJ"},{"key":"589_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"issue":"6","key":"589_CR28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1160\/TH14-10-0859","volume":"113","author":"V Sjogren","year":"2015","unstructured":"Sjogren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register auricula. Thromb Haemost. 2015;113(6):1370\u20137.","journal-title":"Thromb Haemost"},{"key":"589_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1160\/TH13-07-0556","volume":"110","author":"P Gallego","year":"2013","unstructured":"Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013;110:1189\u201398.","journal-title":"Thromb Haemost"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1378\/chest.13-0054","volume":"144","author":"S Apostolakis","year":"2013","unstructured":"Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMEe-TT(2)R(2) score. Chest. 2013;144:1555\u201363.","journal-title":"Chest"},{"key":"589_CR31","doi-asserted-by":"crossref","unstructured":"Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015;1:150\u20132.","DOI":"10.1093\/ehjcvp\/pvv012"},{"key":"589_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","volume":"127","author":"P Gallego","year":"2014","unstructured":"Gallego P, Roldan V, Marin F, et al. SAME-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127:1083\u20138.","journal-title":"Am J Med"},{"key":"589_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1378\/chest.13-2976","volume":"146","author":"GY Lip","year":"2014","unstructured":"Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014;146:719\u201326.","journal-title":"Chest"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0589-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:43:48Z","timestamp":1569977028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0589-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0589-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"12 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}